Equities

Cathay Biotech Inc

Cathay Biotech Inc

Actions
  • Price (CNY)155.55
  • Today's Change1.68 / 1.09%
  • Shares traded206.61k
  • 1 Year change+59.38%
  • Beta--
Data delayed at least 15 minutes, as of Oct 22 2021 04:29 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cathay Biotech Inc is a company engaged in research, development, production and sales of biobased materials. The Company's primary products are biological long-chain dibasic acids, including lauric acid and brazilian acid, which are used in long-chain polyamides, fragrances, hot melt adhesives, lubricants, powder coatings and other areas. The Company sells its products to both domestic and international markets, including the United States, Japan and Europe.

  • Revenue in CNY (TTM)1.72bn
  • Net income in CNY577.65m
  • Incorporated2000
  • Employees1.31k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Elion Energy Co Ltd13.72bn794.32m15.77bn3.96k19.860.9839--1.150.22310.22313.854.500.389530.4311.893,461,629.002.692.584.854.4112.9614.896.905.970.90473.800.39329.891.729.90-48.7331.7338.789.03
JINAN SHENGQUAN GROUP SHARE HLDG CO LTD8.53bn843.28m23.24bn3.53k27.553.8990.282.721.091.0911.017.72------2,417,988.00--------25.17--10.10--1.8814.090.404--41.44--86.12------
Red Avenue New Materials Group Co Ltd2.28bn467.57m29.46bn609.0062.4211.74--12.950.79450.79453.874.220.46916.913.853,735,642.009.7412.6916.0920.8732.8835.0620.7617.411.14--0.493834.19-7.345.5724.1739.8973.35--
Kingfa Sci&Tech Co Ltd37.42bn3.76bn35.85bn10.26k9.542.41--0.95811.461.4614.545.771.137.439.063,647,750.0011.396.7017.2110.5420.3817.8710.075.951.158.790.501943.1219.7217.46268.6445.1612.7543.10
Inner Mngl Jnzhng Eng & CmcI Gp Co Ltd16.29bn5.72bn45.82bn5.51k8.002.24--2.810.67840.67841.932.430.45119.6019.212,956,200.0015.8210.7324.2613.8432.4738.6835.0828.490.936--0.240454.4650.9925.0993.2441.80-6.1497.44
Cathay Biotech Inc1.72bn577.65m65.43bn1.31k109.426.30--38.081.431.434.2824.920.1781.219.271,313,476.006.11--7.51--47.04--34.35--10.69--0.0108---21.87---4.43------
Data as of Oct 22 2021. Currency figures normalised to Cathay Biotech Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.96%Per cent of shares held by top holders
HolderShares% Held
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 20211.06m0.62%
China Asset Management Co., Ltd.as of 30 Jun 20211.03m0.61%
China Merchants Fund Management Co., Ltd.as of 30 Jun 2021726.26k0.43%
E Fund Management Co., Ltd.as of 30 Jun 2021607.95k0.36%
China Universal Asset Management Co., Ltd.as of 30 Jun 2021429.52k0.25%
GF Fund Management Co., Ltd.as of 30 Jun 2021310.00k0.18%
Great Wall Fund Management Co., Ltd.as of 30 Jun 2021297.18k0.18%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2021254.81k0.15%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2021204.10k0.12%
Changsheng Fund Management Co., Ltd.as of 30 Jun 2021112.90k0.07%
More ▼
Data from 31 Mar 2021 - 15 Oct 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.